Viewing Study NCT00357409



Ignite Creation Date: 2024-05-05 @ 4:57 PM
Last Modification Date: 2024-10-26 @ 9:26 AM
Study NCT ID: NCT00357409
Status: COMPLETED
Last Update Posted: 2017-07-02
First Post: 2006-07-26

Brief Title: GABA Levels in the Brains of Blind People
Sponsor: National Institute of Neurological Disorders and Stroke NINDS
Organization: National Institutes of Health Clinical Center CC

Study Overview

Official Title: GABA Levels in the Occipital Cortex of Blind Human Subjects
Status: COMPLETED
Status Verified Date: 2008-03-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: In blind individuals the occipital cortex becomes capable of processing tactile and auditory information a phenomenon described as crossmodal plasticity GABA is the major inhibitory neurotransmitter in the brain and a possible candidate to mediate this form of human plasticity We intend to use magnetic resonance spectroscopy MRS to measure GABA and hypothesize that GABA levels in the occipital cortex of blind humans will be lower than in sighted controls Such decrease could possibly mediate compensatory changes in the occipital cortex of the blind

Objective

Early blind subjects exhibit better tactile acuity than late blinds or sighted individuals The purpose of the study is the determine GABA levels in the human occipital cortex after long-term light deprivation blindness

Study Population

Our experiments will make use of early blind late blind and sighted control subjects

Design

Subject will be identified and will receive clinical and neurological examinations at the NIH MRS studies will be performed at NIH MRI Center with 3Tesla Magnet Each subject head will be positioned in an adjustable holder designed for minimal motion and maximal comfort such that a flat coil lay just below the occipital cortex The sequence has been described before 33 The individuals who perform the data analysis will be blind to the purpose of the experiments

Outcome measures

The concentration of GABA from the 14 ml voxel over the visual cortex will be measured Edited proton spectrum of GABA will be compared with the edited sub spectrum of creatine for a concentration reference
Detailed Description: In blind individuals the occipital cortex becomes capable of processing tactile and auditory information a phenomenon described as crossmodal plasticity GABA is the major inhibitory neurotransmitter in the brain and a possible candidate to mediate this form of human plasticity We intend to use magnetic resonance spectroscopy MRS to measure GABA and hypothesize that GABA levels in the occipital cortex of blind humans will be lower than in sighted controls Such decrease could possibly mediate compensatory changes in the occipital cortex of the blind

Objective

Early blind subjects exhibit better tactile acuity than late blinds or sighted individuals The purpose of the study is the determine GABA levels in the human occipital cortex after long-term light deprivation blindness

Study Population

Our experiments will make use of early blind late blind and sighted control subjects

Design

Subjects will be identified and will receive clinical and neurological examinations at the NIH MRS studies will be performed at NIH MRI Center with 3Tesla Magnet Each subject head will be positioned in an adjustable holder designed for minimal motion and maximal comfort such that a flat coil lay just below the occipital cortex The sequence has been described before The individuals who perform the data analysis will be blind to the purpose of the experiments

Outcome measures

The concentration of GABA from the 14 ml voxel over the visual cortex will be measured Edited proton spectrum of GABA will be compared with the edited sub spectrum of creatine for a concentration reference

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
02-N-0124 None None None